You are here: Industry Insights > COPD

News List

Lung function of COPD patients improved with Ultibro Breezhaler europeanpharmaceuticalreview
November 28, 2017
Novartis has announced positive results from the FLASH study examining the safety and efficacy of directly switching COPD patients from Seretide to Ultibro Breezhaler…
COPD survey reveals gaps in care pharmatimes
November 20, 2017
A survey of 500 people across Britain diagnosed with chronic obstructive pulmonary disease (COPD) has revealed that almost a third (31 percent) feel their treatment is not adequately controlling their condition.
GSK gets EU go-ahead for triple therapy inhaler in COPD .pharmafile
November 17, 2017
The EMA has awarded EU marketing authorisation to GlaxoSmithKline and Innovia’s single inhaler triple therapy Trelegy Ellipta for the treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema, it has emerged.
GSK’s Anoro Ellipta beats BI’s Spiolto Respimat in COPD trial pharmatimes
November 03, 2017
GlaxoSmithKline and Innoviva say their combination lung therapy Anoro Ellipta has come out on top in a trial pitting its effectiveness in improving lung function against that of Boehringer Ingelheim’s Spiolto Respimat.
Singapore conducts research on asthma and COPD biospectrumasia
October 19, 2017
The $1.2 million study aims to create a database for research into respiratory diseases.
SingHealth, Duke NUS and GSK join forces for study on asthma and COPD in Singapore biospectrumasia
October 18, 2017
Singapore has one of the highest asthma prevalence rates in the world, with around one-in-five children and five per cent of adults diagnosed with the condition
Steroid inhalers increase the risk of hard-to-treat infections europeanpharmaceuticalreview
September 22, 2017
Older people who use steroid inhalers are more likely to suffer particular bacterial infections…
GSK and Innoviva receive positive opinion from CHMP for Trelegy Ellipta to treat COPD pharmaceufical-technology
September 19, 2017
Trelegy Ellipta is the proposed brand name for fluticasone furoate / umeclidinium / vilanterol (FF / UMEC / VI), which is co-developed by GlaxoSmithKline (GSK) and Innoviva.
GSK receives positive opinion for triple-therapy inhaler pharmafile
September 18, 2017
GSK, alongside its partner Innoviva, has announced that it has received a positive opinion from the EMA’s CHMP for its Trelegy Ellipta treatment for chronic obstructive pulmonary disease (COPD).
GlaxoSmithKline, Propeller widen respiratory sensor collaboration for COPD edge fiercepharma
August 25, 2017
Just weeks after appointing a new chief digital officer, Karenann Terrell, GlaxoSmithKline is pushing its digital efforts with an expanded Propeller Health collaboration.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page